New combo therapy aims to fight cancer while easing harsh side effects
NCT ID NCT05034536
Summary
This study is testing if adding a drug called infliximab to standard immunotherapy helps people with advanced melanoma. The goal is to see if this combination can better control the cancer while also reducing the severe digestive side effects that immunotherapy sometimes causes. About 36 adults with metastatic melanoma who haven't had this type of treatment before will participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.